Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

CSE:RVV - Post Discussion

Revive Therapeutics Ltd > $RVV $RVVTF - Great Post on Yahoo ! James - Thank U !!
View:
Post by cool888 on May 03, 2021 4:15pm

$RVV $RVVTF - Great Post on Yahoo ! James - Thank U !!

“Finally”, we’re getting somewhere!, there’s no better way to gain credibility or support for Bucillamine than to allow a University such as the University of California, San Francisco (“UCSF”) to explore the efficacy of Bucillamine as a treatment for severe COVID-19, it’s quite obvious to me that the 3rd phase of this journey for the treatment of mild to moderate COVID has done well for REVIVE TO even entertain the idea of exploring the utility of Bucillamine as a severe treatment for COVID-19, I really don’t care what anyone else has to say, I just want to see “results”, because this has been such a long and drawn out process, for a proven safe 30 year old anti inflammatory drug that under these unprecedented circumstances should have flew through the testing process as government should have backed this as well!!, Revive has been lobbying the FDA from the very beginning to be fast tracked!!, not once has the Canadian or US government shown any significant “if any” support at all!, I started buying shares in RVV.CN as a psychedelic play to which probably would have done much better without Bucillamine as a distraction!?, many fantastic breakthroughs and data have come through Revive Therapeutics amazing pipeline, this is a cannibinol/psychedelic company that has pioneered many breakthroughs especially in the development of Cannabidiol ( CBD) for the treatment of many rare diseases like autoimmune hepatitis a rare liver disease in the prevention of ischemia and reperfusion injury resulting from organ transplants such as liver, heart, kidney and lung. their work with psychedelics from treatments to delivery systems have all been unprecedented as their pipeline continues to grow and they continue to ramp up clinical trials and phases. It’s seems that with all their advances and breakthroughs are continuously canceled out by the hype and focus that’s been placed solely on their phase 3 clinical testing!!. On a positive note, their BUCILLAMINE treatments must be doing quite well and satisfying all the end points or they wouldn’t have pursued another research agreement!!, when this finally does come to a head it should all unfold in stages, mild to moderate approval to severe approvals for treatment of the COVID-19 virus, Face it there’s a lot sick people out there that will continue to get sick from this virus, many who have made it through are still left with lung damage or breathing problems, bucillamine showed promise in treating patients with these residual symptoms and effects, hopefully bucillamine is given FDA and Health Canada approval soon so that people can get on with their life and we as patient long investors can move on with ours!!, still bullish and still think investors will be pleasantly surprised by the final outcome!, I think at this point and I don’t blame them, but Revive Therapeutics just wants to cross all their t’s” and dot all their “I”s making sure that all the bases have been covered. GLTA!!
Comment by 1ottrunner on May 03, 2021 4:54pm
Nice dream but not likely. If MF or Doc F had any data on this blinded study they would have to share it with us, not in a month, not in 2 weeks, right away.  ASAP sort of thing. We can all dream of great trial results but until they are posted we have no idea, in fact it is just as LIKELY that they are moving to pre-clinical testing in severe illness because the trial has FAILED. I am in ...more  
Comment by cool888 on May 03, 2021 5:14pm
It's ALWAYS a pleasure to read your NEGATIVE posts ... In coming weeks, EUA news !! O Yeah !!
Comment by 1ottrunner on May 03, 2021 6:59pm
Cool88, is it more likely that a clinical trial succeeds or fails?
Comment by cool888 on May 03, 2021 7:20pm
BIG YES - SUCCESS ! my friend, in my opinion !! Revive cannot discuss preliminary findings prior to the data being reviewed but it's very obvious the results are favorable or they would not be expanding the scope of the research to include the efficacy in sever covid. EUA News Very Soon - GLTA folks !!
Comment by 1ottrunner on May 03, 2021 7:24pm
You did not answer the question Cool888. -->Do most clinical trials succeed or do more fail?
Comment by cool888 on May 03, 2021 7:49pm
Am you talking about REVIVE only. just think about it........ If you can't run a block (mild), can't even run two blocks (moderate), why would you want to sign up to run a marathon ? In my humble opinion, MF send this PR this morning to ALERT every shareholder/investor a message to which he cannot say, atleast officially in a PR form that IT IS A SCCUESS so far and read in between lines, ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities